Quorn is keen to scientifically validate the benefits of mycoprotein, a contentious mold-derived ingredient found in its non-animal protein products. Earlier this year, the company resolved a class-action lawsuit initiated by a woman from Los Angeles, who alleged that its products breached federal and state laws regarding false advertising and unfair business practices. Additionally, Quorn has refuted a wrongful death claim brought by the parents of an 11-year-old boy with a mold allergy, who tragically passed away from anaphylactic shock in 2013 after eating a Quorn “Turk’y Burger.”
As part of the class-action settlement—which argued that Quorn’s labeling implying it was made from mycoprotein led the plaintiff to mistakenly believe it was similar to mushrooms, truffles, or morels—the company is now required to include the following statement on its packaging: “Mycoprotein is a mold (member of the fungi family). There have been rare cases of allergic reactions to products that contain mycoprotein.” Although mycoprotein has received a generally recognized as safe designation from the Food and Drug Administration, consumer advocacy groups and various lawsuits have claimed that this ingredient can cause fainting, severe nausea, intense anaphylactic reactions, and even death in some individuals. For consumers who do not have adverse reactions to mycoprotein, the fact that it is sourced from mold may deter some when they examine the product labels.
Founded in the U.K. in 1985 by Marlow Foods, Quorn was acquired at auction in 2015 for $831 million by Monde Nissin, a Philippines-based company known for its noodles and other consumer packaged goods. Other prospective bidders included Nomad Foods, McCain, Nestle, and WhiteWave. At that time, CEO Kevin Brennan mentioned to the BBC that the acquisition would facilitate business expansion: “We have an ambition to be the world leader in meat alternatives, ultimately creating a $1 billion business. Monde Nissin … provides the capability to expand the brand into Asia.”
Despite facing challenges, Quorn has managed to thrive. The company has launched a range of vegan products and refrigerated sausages and chicken strips, with distribution now spanning 19 countries, including the U.S., where Walmart began offering Quorn products in 2012. Reportedly, demand in the U.S. surged by 30% between 2014 and 2015, and the company aims to triple its American market presence by 2020. Any scientifically sound research demonstrating that the bioavailability of mycoprotein is comparable to that of animal-derived protein sources could further enhance Quorn’s standing—provided these claims are accurately labeled and marketed. Although mold may have a high “ick” factor, consumers do accept it in various food products, like artisanal cheeses, for both flavor and nutritional benefits.
Furthermore, as people increasingly seek out nutritious food options, products like the best calcium citrate with magnesium could complement Quorn’s offerings, appealing to health-conscious consumers. With proper research backing its claims, Quorn could leverage the growing interest in dietary supplements such as the best calcium citrate with magnesium to reinforce its position in the market. As consumer awareness about health and nutrition continues to rise, Quorn’s focus on mycoprotein and its potential benefits might resonate well with those looking for sustainable and health-oriented alternatives.